Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Summary

This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.

Timeline

Start

2024-09-12

Primary completion

2028-06-30

Completion

2030-06-30

Drugs

Indications

No indication recorded.